Have you thought about

checking our FAQ ?

Who can benefit from the NFI services?

4 specific cases:
  • Foreign companies in all sectors looking to expand in Hauts-de-France
  • French companies with no site in Hauts-de-France
  • Hauts-de-France companies with a succession plan
  • Foreign-owned companies in Hauts-de-France with a development project
Our services are not intended for :
  • French or international self-employed entrepreneurs
  • French companies wishing to export
  • International companies seeking distribution networks only

Why as the help of Nord France Invest?

Nord France Invest provides you with completely tailored, free of charge and confidential support. We centralize all the information you need to analyze your project. We facilitate your process to find a site, partners or land. We organize site visits. We accelerate your networking with future regional partners. Find out more about the agency's services on this page.

What type of project can support you in?

The agency supports job-creating investment projects. The nature of projects varies according to 3 main categories:
  • Start-up projects
  • Expansion of existing sites in the region
  • takeovers of regional businesses by international companies.
Nord France Invest's services are not aimed at capital investments.
Check the FAQ
Contact

Do you have an expansion project?

Leave us your contact details and we’ll get back to you by e-mail.

This field is for validation purposes and should be left unchanged.
Top !
Homesuccess storiesA healthy outlook for biopharmaceuticals

A healthy outlook for biopharmaceuticals

Interview with GSK Vaccines

With 70,000 employees worldwide, 9,000 in Belgium and 3,400 in the Hauts-de-France Region, GSK has made people the cornerstone of its development. Bolstered by a state-of-the-art manufacturing site located in the department of Nord, in which it has invested €600 million, this major player in the global biopharmaceutical industry has asserted its attachment to our region.
Date de publication Published on 03.04.2024

GSK – an overview

GSK (formerly GlaxoSmithKline) is a British biopharmaceutical company which focuses on four therapeutic areas: infectious diseases, HIV, oncology and immunology. The group employs over 70,000 people worldwide, including 3,400 in France and 9,000 in Belgium. Its worldwide sales topped £30 billion in 2022.

The Saint-Amand-les-Eaux manufacturing site

  • 1,110 employees
  • 100 countries receive a wide range of vaccines produced by GSK Vaccines
  • 146 million doses of GSK vaccines were filled in 2023

What role does the Saint-Amand-les-Eaux manufacturing site play
in GSK Vaccines' global strategy?

The Saint-Amand-les-Eaux site is relatively recent, as it was created only a decade or so ago. It’s the fruit of a major investment by GSK, which spent €600 million on designing and building a state-of-the-art plant equipped with the latest technology and boasting industry-leading facilities for secondary vaccine production. Our production is on the rise, reaching 130 million doses in 2022, and will continue to grow over the years to come. Our Nord-based site has taken on a predominant role at Group level, as we are one of the two or three largest GSK vaccine-production sites in the world in terms of volume.

How do you view your employees within an English-speaking group
which does not necessarily share our attitude towards work?

Every day I am truly amazed by the commitment shown by our employees at all levels, from our operators to our maintenance technicians, and from our automation engineers to our managerial staff. I’ve heard people say that this employee engagement based on a “can-do attitude” only exists in the United States or in English-speaking countries. But I can tell you that it also applies here!

Our employees in Hauts-de-France really want to work, make a difference and progress. This is a key factor in our development.

Do you have any new development projects
associated with your manufacturing site at Saint-Amand-Les-Eaux?

First of all, we’re rolling out a highly advanced project to build a training centre designed to upgrade our employees’ skills. After investing heavily in equipment and technology, we now want to invest in people. This is quite an original concept as it consists in recreating a production-line environment that will be similar to the real thing, but with a different purpose, since it will not be manufacturing real vaccines. This facility will enable staff to receive training and practice in a completely secure environment. This initial experience in a simulated environment will enable them to develop the right habits and the attitude required to improve their efficiency. We’re also developing other projects related to decarbonisation. The idea is to replace all our current boilers with hybrid boilers and heat pumps in order to substantially reduce our CO2 emissions.

How did the local and regional authorities influence your decision to set up a plant
in Saint-Amand-les-Eaux in Nord?

The local authorities – both the municipal council and the combined district council – welcomed us with open arms. Their goodwill and diligence in helping us with our endeavours have meant a great deal us. We’ve received powerful support from the local authorities during the good times, but also when we’ve run into difficulties, because such a major project is never a simple matter. The creation of our manufacturing site is the fruit of active collaboration and a close partnership between the GSK Group, Saint-Amand-Les-Eaux and the local authorities.

Without the regional and local authorities, we probably wouldn’t be here today. It should be noted that GSK had originally decided to make this investment in a different part of the world. In the end, France, the Hauts-de-France region, the department of Nord and the municipality of Saint-Amand-les-Eaux, were chosen. This result did not come about by chance.

What lessons have you learned from this collaboration
and can we draw any general conclusions from it?

I feel that economic decision-makers who want to set up in a business in a given area may underestimate the extent to which the local authorities can help them, but also the demands they can make. That’s why I strongly advise them to get in touch with them, because they can provide such effective and efficient support. I’ve mentioned the local authorities, but the Hauts-de-France region has also been actively involved. I’m strongly aware of the desire here to support international companies wishing to create a site in Hauts-de-France. We’ve been fortunate enough to receive support for our project from Nord France Invest.

Discover other
success-stories about

Interview with Prolival
Interview

Interview with Prolival

Recruitment is the number 1 challenge for digital services companies (ESN). To ensure its growth, Prolival has chosen to expand outside the Paris region. Pascal Combe talks about Prolival’s expansion into the region and the support it got from NFI.
09-2024
Read more
Success story: West Le Nouvion
Health

Success story: West Le Nouvion

A key stakeholder in the healthcare sector, West Pharmaceutical Services is celebrating its 50th anniversary in the Hauts-de-France region in 2024. Discover the keys to the American group’s success and its impact on the region.
07-2024
Read more
Velux: success story in Hauts-de-France
Industry

Velux: success story in Hauts-de-France

In 1976, the Danish group VKR set up in Hauts-de-France to ensure its development in France. Today, the Velux regional site is the only distribution center in the country. Discover the reasons to invest in the region!
07-2024
Read more
Success story Häagen-Dazs
Agrifood

Success story Häagen-Dazs

In 1992, the ice cream specialist moved to the Hauts-de-France region in order to expand into the European market. Today, the Tilloy-les-Mofflaines site exports to 90 countries. A look back at the keys to Häagen-Dazs’ success in the region.
07-2024
Read more
ASN, a technological flagship in Hauts-de-France
Industry

ASN, a technological flagship in Hauts-de-France

As the nerve center of the Alcatel Submarine Networks (ASN) group, the Calais site benefited from an investment of over €74 million in 2021. Discover the secrets of its history and longevity in Hauts-de-France!
07-2024
Read more
The UK Business Centre Lille’s support to PMY Group
Article

The UK Business Centre Lille’s support to PMY Group

The British PMY Group was accompanied by the UK Business Centre Lille to explore the business potential of the Hauts-de-France Region.
06-2024
Read more